The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease
Abstract
The cause and mechanism of neuronal cell death in the substantia nigra of patients with Parkinson's disease (PD) are unknown. There is also controversy about whether the cell death results from a single event followed by cell loss consistent with aging or whether there is an ongoing pathologic process. Using postmortem tissue obtained from the Parkinson's Disease Society Brain Tissue Bank in London, we have sought to establish whether apoptosis, or more specifically DNA fragmentation of neurons, is a prominent feature of nigral pathology. In addition, we have studied microglial activation in the substantia nigra as an indicator of ongoing pathology using the highly sensitive markers CR3/43 and EBM11. Reactive astrocytes have been assessed using immunostaining for glial fibrillary acidic protein (GFAP). Ten patients with pathologically proven PD were studied. In all cases, regardless of disease duration, severity, drug treatment, or age of the patient, there was no evidence of apoptosis in the substantia nigra as assessed by in situ end‐labeling of DNA fragments using biotinylated dUTP and terminal deoxynucleotidyl transferase (TdT). In contrast, a case of multiple system atrophy (MSA) served as a positive control for the technique. In this case, positive DNA end‐labeling could be found in neurons and non‐neuronal cells in the brain stem. In the PD cases, there was, however, localized pathology in the substantia nigra as revealed by the CR3/43 and EBM11 markers for activated microglia. This process seemed independent of disease duration and was florid even in patients with severe neuronal loss. It remains to be determined to what extent the activation of glial cells reflects progressive nigral pathology, and whether those factors which are classically associated with prominent apoptotic neuronal cell death in vivo, such as neurotrophic factor deprivation, are prime causes of nigral neuronal loss in PD. Future studies should focus on recent‐onset PD or incidental Lewy body disease to further address these questions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Death: The Significance of Apoptosis
Wyllie, A. H., Kerr, J. F. R., & Currie, A. R. (1980) · International Review of Cytology · doi:10.1016/s0074-7696(08)62312-8 · Cited by 7,162
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 753
Gold, R., Schmied, M. C., Giegerich, G., Breitschopf, H., Hartung, H., Toyka, K. V., & Lassmann, H. (1994) · PubMed · Cited by 675
Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
Portera-Cailliau, C., Hedreen, J., Price, D., & Koliatsos, V. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03775.1995 · Cited by 607
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
Lassmann, H., Bancher, C., Breitschopf, H., Wegiel, J., Bobinski, M., Jellinger, K., & Wisniewski, H. M. (1995) · Acta Neuropathologica · doi:10.1007/bf00294257 · Cited by 458
Oxidative damage in neurodegenerative disease
Jenner, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92347-7 · Cited by 418
Research works printed but not linked: 3
- Forno LS, 1971, Recent Advances in PD, 120
- Anglade P, 1996, Apoptotic degeneration of nigral dopaminergic neurons in Parkinson's disease [Abstract], Neurology, 46, A467
- Morrish PK, 1994, The rate of progression of PD: a longitudinal 18F‐DOPA PET study [Abstract], Journal of Neurochemistry, 8, 198
Cited by
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Middeldorp, J., & Hol, E. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.005 · Cited by 1,080
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Gao, H., Jiang, J., Wilson, B., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 687
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Neuronal caspase-3 signaling: not only cell death
D'Amelio, M., Cavallucci, V, & Cecconi, F. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.180 · Cited by 525
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3039 · Cited by 449
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
Particulate Matter in Polluted Air May Increase Biomarkers of Inflammation in Mouse Brain
Campbell, A., Oldham, M., Becaria, A., Bondy, S. C., Meacher, D., Sioutas, C., Misra, C., Mendez, L. B., & Kleinman, M. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2004.08.003 · Cited by 421
Tatton, N. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7489 · Cited by 411
Cicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Apoptosis in Parkinson's disease: Signals for neuronal degradation
Tatton, W. G., Chalmers-Redman, R., Brown, D., & Tatton, N. (2003) · Annals of Neurology · doi:10.1002/ana.10489 · Cited by 397
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Inhibition of Microglial Phagocytosis Is Sufficient To Prevent Inflammatory Neuronal Death
Neher, J. J., Neniskyte, U., Zhao, J.-W., Bal-Price, A., Tolkovsky, A. M., & Brown, G. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003600 · Cited by 373
Montgomery, S. L., & Bowers, W. J. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9287-2 · Cited by 366
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363
Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., Cuzzocrea, S., Zappia, M., Giordano, J., Calabrese, E. J., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.379 · Cited by 356
Vegeto, E., Benedusi, V., & Maggi, A. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.04.001 · Cited by 355
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 350
Jellinger, K. A. (1999) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6360-3_1 · Cited by 347
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337
Mirza, B., Hadberg, H., Thomsen, P., & Moos, T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00455-8 · Cited by 327
The role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R., Anisman, H., Hayley, S., & Park, D. S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 315
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296
Neuroinflammatory processes in Parkinson's disease
Hirsch, E. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 296
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Cernak, I., Merkle, A. C., Koliatsos, V. E., Bilik, J. M., Luong, Q. T., Mahota, T. M., Xu, L., Slack, N., Windle, D., & Ahmed, F. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.025 · Cited by 285
Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050028 · Cited by 282
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Apoptosis and neurologic disease
Honig, L. S., & Rosenberg, R. N. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00291-6 · Cited by 261
Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 258
Zhang, W., Phillips, K., Wielgus, A. R., Liu, J., Albertini, A., Zucca, F. A., Faust, R., Qian, S. Y., Miller, D. S., Chignell, C. F., et al. (2011) · Neurotoxicity Research · doi:10.1007/s12640-009-9140-z · Cited by 257
Sriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
Zecca, L., Wilms, H., Geick, S., Claasen, J.-H., Brandenburg, L.-O., Holzknecht, C., Panizza, M. L., Zucca, F. A., Deuschl, G., Sievers, J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0361-7 · Cited by 205
Zangaglia, R., Martignoni, E., Glorioso, M., Ossola, M., Riboldazzi, G., Calandrella, D., Brunetti, G., & Pacchetti, C. (2007) · Movement Disorders · doi:10.1002/mds.21243 · Cited by 177
Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons
Rite, I., Machado, A., Cano, J., & Venero, J. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04567.x · Cited by 147
Striatal Neuroinflammation Promotes Parkinsonism in Rats
Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141
Jyothi, H. J., Vidyadhara, D. J., Mahadevan, A., Philip, M., Parmar, S. K., Manohari, S. G., Shankar, S. K., Raju, T. R., & Alladi, P. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.024 · Cited by 139
Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments
Poirier, A.-A., Aubé, B., Côté, M., Morin, N., Di Paolo, T., & Soulet, D. (2016) · Parkinson s Disease · doi:10.1155/2016/6762528 · Cited by 130
Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
Influence of neuromelanin on oxidative pathways within the human substantia nigra
Double, K. L., Ben-Shachar, D., Youdim, M. B. H., Zecca, L., Riederer, P., & Gerlach, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00218-0 · Cited by 102
DJ‐1 deficiency impairs autophagy and reduces alpha‐synuclein phagocytosis by microglia
Nash, Y., Schmukler, E., Trudler, D., Pinkas‐Kramarski, R., & Frenkel, D. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14222 · Cited by 100
Exercise and Neuroinflammation in Health and Disease
Seo, D.-Y., Heo, J.-W., Ko, J. R., & Kwak, H.-B. (2019) · International Neurourology Journal · doi:10.5213/inj.1938214.107 · Cited by 88
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Sugama, S., Takenouchi, T., Fujita, M., Kitani, H., & Hashimoto, M. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.11.002 · Cited by 55
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Short-term effects of an endotoxin on substantia nigra dopamine neurons
Reinert, K. R. S., Umphlet, C. D., Quattlebaum, A., & Boger, H. A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.02.005 · Cited by 28
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Metadata
- Authors
- Banati, R. B., Daniel, S. E., & Blunt, S. B.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1998-03
- Volume
- 13
- Issue
- 2
- Pages
- 221-227
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2011850283
- Cited by
- 431
- References
- 19
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.